Welcome to our dedicated page for Marimed news (Ticker: MRMD), a resource for investors and traders seeking the latest updates and insights on Marimed stock.
MariMed Inc. (MRMD) generates frequent news as a multi-state cannabis operator and cannabis consumer packaged goods company focused on branded products, facility operations, and regulatory developments. Its releases cover both corporate performance and brand-level activity across cultivation, production, and retail channels.
On this page, readers can follow MariMed’s earnings announcements, where the company discusses revenue trends, gross margins, net income or loss, and non-GAAP measures such as Adjusted EBITDA. These updates often include commentary on wholesale and retail performance, as well as progress on what management calls its "Expand the Brand" strategy to grow top-selling cannabis brands.
MariMed’s news flow also highlights product and brand developments. Examples include new limited-edition Betty’s Eddies™ fruit chews, extensions to the Nature’s Heritage™ product line, and initiatives for Vibations™ and InHouse™. The company reports on licensing and managed services agreements that bring its brands into additional states, as well as strategic decisions such as exiting specific markets after operational reviews.
In addition, MariMed issues releases on community and veteran-focused initiatives tied to its Thrive dispensaries and brands, along with commentary on major policy changes affecting cannabis, such as the rescheduling of cannabis at the federal level. Investors and observers can use this news feed to monitor how MariMed communicates its strategy, brand expansion, financial performance, and responses to regulatory and market changes over time.
MariMed Inc. (CSE: MRMD) has opened its third adult-use dispensary in Massachusetts under the brand Panacea Wellness in Beverly, enhancing its presence in the Boston area. This marks the company’s tenth dispensary across four states. The grand opening will occur from April 27 to April 29, featuring entertainment and free merchandise. The company also operates a cultivation facility in New Bedford and plans to maximize its footprint in Massachusetts, which generated $1.8 billion in cannabis sales in 2022. MariMed offers a range of premium cannabis products, including Nature’s Heritage and Betty’s Eddies. The company's strategic expansion demonstrates its commitment to capturing market share in a rapidly growing industry.
MariMed Inc. (CSE: MRMD, OTCQX: MRMD) has appointed Kathleen Tucker to its Board of Directors, enhancing its leadership in the cannabis sector. Tucker brings over 25 years of experience in consumer marketing, product development, and operations. She has previously served as CEO of Presence Enterprises and COO of MariMed's subsidiary and 3C Compassionate Care Center. Tucker holds an MBA and B.S. in Operations and Computer Science from Northern Illinois University. MariMed aims to strengthen its brand appeal and customer experience with Tucker's insights, as stated by CEO Jon Levine. The company continues to focus on high-quality, innovative cannabis products across its multiple operations.
MariMed Inc. (CSE: MRMD, OTCQX: MRMD), a leading multi-state cannabis operator, will report its Q1 2023 financial results on May 8, 2023, after market close. Management will host a conference call on May 9, 2023, at 8:00 a.m. EST to discuss the financial outcomes. The call will be accessible via a webcast on MariMed’s Investor Relations website, where a playback will also be available. MariMed is dedicated to improving lives through its high-quality cannabis products, utilizing state-licensed facilities and proprietary formulations that underpin its popular brands such as Betty's Eddies and Nature’s Heritage.
MariMed (CSE: MRMD) announced that its subsidiary, Kind Therapeutics USA, has received approval from the Maryland Medical Cannabis Commission to produce and distribute higher-dosage THC-infused edibles. Following the acquisition of Good Manufacturing Practice (GMP) certification for its Hagerstown facility, MariMed can now offer 40mg products, starting with the popular Betty’s Eddies fruit chews. This move comes as Maryland prepares for adult-use cannabis sales, expected to begin in July 2023. The company operates a 90,000 square foot production facility and has a strong presence across over 100 dispensaries statewide, positioning itself for significant growth.
MariMed Inc. (CSE: MRMD, OTCQX: MRMD), a prominent multi-state cannabis operator, recently announced its participation in key investor conferences. CEO Jon Levine will speak at the Benzinga Cannabis Capital Conference on April 11 in Miami, engaging in a panel on growth insights for 2023 and a fireside chat on April 12. CFO Susan Villare will conduct one-on-one meetings at Canaccord Genuity's 7th Annual Global Cannabis Conference in New York on May 18. MariMed focuses on excellence in cannabis cultivation and infused products, offering top-selling brands like Betty's Eddies and Nature’s Heritage.
MariMed, Inc. (CSE: MRMD) has successfully completed the acquisition of Ermont Inc.'s operating assets, enhancing its presence in Massachusetts as the second medical dispensary opens under the Panacea Wellness brand. This acquisition, finalized on March 9, 2023, follows the Company’s goal of maximizing its footprint within state regulations. The deal includes two Host Community Agreements, one for adult-use cannabis sales, and plans to expand operations to meet growing demand. The transaction, the first cannabis receivership in New England, was approved by the Massachusetts Cannabis Control Commission, offering a strategic advantage in the evolving cannabis market.
MariMed reported its financial results for Q4 and full-year 2022, highlighting a revenue increase to $35.8 million for the quarter, up from $31 million in Q4 2021. Full-year revenue reached $134 million, marking a growth from $121.5 million in 2021. The company achieved a GAAP net income of $4.8 million, a positive turnaround from a loss of $6.4 million in Q4 2021. Positive cash flows from operations were maintained for the third consecutive year. For 2023, MariMed anticipates revenues exceeding $150 million and plans to open four new dispensaries. The company aims to leverage its strong balance sheet and operational capabilities for accelerated growth.
FAQ
What is the current stock price of Marimed (MRMD)?
What is the market cap of Marimed (MRMD)?
